Company Overview - ACADIA Pharmaceuticals Inc. is a biopharma firm listed on NASDAQ under the ticker ACAD, with a portfolio that includes two commercial drugs: Nuplazid and Daybue [1] Product Details - Nuplazid is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP) [1] - Daybue is indicated for the treatment of Rett syndrome [1]

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 SOURCE Pomerantz LLP The investigation concerns whether Acadia and certain of its officers and/or directors have engaged in securities fraud or other unlawful business pra ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced one late- breaker oral platform presentation and two poster presentations to be presented at the International Congress of Parkinson's Disease and Movement Disorders® being held October 5-9, 2025, in Honolulu, Hawaii. The presentations highlight updates from the company's robust pipeline including preclinical efficacy, safety and mechanism of action findings on Acadia's investigational drug ACP-711, under deve. ...

Key Takeaways Acadia's ACP-101 failed to show benefit in phase III PWS study, ending its development.Nuplazid and Daybue sales rose double digits in H1 2025, fueling ACAD's revenue growth.SLNO stock jumped as Vykat XR gains ground with ACAD exiting the PWS hyperphagia market.Shares of Acadia Pharmaceuticals (ACAD) lost 9.9% on Wednesday after the company announced a disappointing update from a late-stage study of its investigational candidate, intranasal carbetocin (ACP-101), in patients with hyperphagia in ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, inte ...

Acadia Pharmaceuticals Inc. ACAD released topline results on Wednesday from its Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin (ACP-101) in patients with hyperphagia in Prader-Willi syndrome (PWS).PWS is a rare genetic disorder characterized by muscle weakness and feeding difficulties in infancy, followed by an insatiable hunger and tendency toward severe obesity starting in childhood. PWS also involves delayed development, intellectual disability, behavioral issues an ...

BREAKING: Futures Edge Up, Alibaba Leads China Stocks Higher Shares of Acadia Pharmaceuticals (ACAD) toppled Wednesday after the biotech company's experimental treatment for a rare, genetic disorder failed in Phase 3 testing. Analysts largely expected the drug, dubbed carbetocin, to miss its mark in patients with Prader-Willi syndrome. In this condition, a deletion or mutation of a specific gene causes physical, intellectual, developmental and behavioral symptoms. Acadia intended for its drug to treat exces ...

Acadia Pharmaceuticals said on Wednesday that its experimental therapy to treat a rare metabolic condition failed to meet the main goal in a late-stage study. ...

Summary of Acadia Pharmaceuticals FY Conference Call Company Overview - **Company**: Acadia Pharmaceuticals (NasdaqGS:ACAD) - **Event**: FY Conference held on September 18, 2025 Key Points on Prader-Willi Syndrome (PWS) Program - **Upcoming Data**: Top line phase 3 COMPASS data for ACP-101 (carbetocin) expected in early Q4, possibly October [3][4] - **Mechanism of Action**: ACP-101 is a modified version of oxytocin, designed to enhance pharmacokinetics and selectivity for the oxytocin receptor, which is relevant for treating hyperphagia in PWS [4][5] - **Animal Studies**: Evidence suggests that oxytocin replacement can mitigate hyperphagic behaviors in animal models of PWS [5] - **Clinical Trials**: Previous oxytocin studies showed mixed efficacy results but consistent safety and tolerability [7] - **Inverse Dose Response**: Prior phase 3 trial indicated an inverse dose response, with a significant p-value of 0.016 for the lower 3.2 mg dose compared to placebo [12] - **Safety Profile**: No serious adverse events reported in previous studies; some nosebleeds observed at higher doses [16][17] COMPASS Study Design - **Enrollment**: Target of 170 patients, randomized 1:1 between 3.2 mg dose and placebo [20] - **Primary Endpoint**: HQ-CT to measure hyperphagia-related behaviors [20][21] - **Secondary Endpoints**: Include clinician global impressions and caregiver burden assessments [21] ACP-204 Development - **New Compound**: ACP-204 is a next-generation 5HT2A inverse agonist aimed at treating Alzheimer's disease psychosis and Lewy body dementia [27][28] - **Study Design**: Phase 2 study with 318 patients, operationally seamless with phase 3 [29] - **Primary Endpoint**: SAPS-H and D at week six [29] - **Biomarker Confirmation**: Required for Alzheimer's disease psychosis patients, but not for Lewy body dementia [36][37] ACP-211 Overview - **New Compound**: ACP-211 is a noradrenaline compound for major depressive disorder (MDD) [38] - **Phase 2 Study**: Set to start in Q4 with 150 patients, focusing on moderate response [40] - **Safety Profile**: Aims for ketamine-like efficacy without sedation or significant dissociation [39][41] Business Development Strategy - **Focus Areas**: Emphasis on neuropsychiatry and rare diseases, particularly phase 2 assets [42] - **Pipeline Catalysts**: Key upcoming data includes ACP-101 in early Q4 and initiation of several new trials [43] Additional Insights - **Stakeholder Engagement**: Positive feedback from KOLs and caregivers regarding the potential treatment options for PWS [25] - **Regulatory Considerations**: FDA's focus on HQ-CT as a primary efficacy endpoint for approval [24] This summary encapsulates the critical insights and developments discussed during the Acadia Pharmaceuticals FY Conference, highlighting the company's ongoing research and strategic direction in neuropsychiatry.

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the journal Developmental Medicine and Child Neurology published interim results from the caregiver-reported observational online, open-label, ongoing LOTUS study evaluating effectiveness and tolerability outcomes in patients with Rett syndrome who are prescribed DAYBUE® (trofinetide) under routine clinical care in the U.S. Findings included reported improvements in symptoms of Rett syndrome, with early. ...